IGM Biosciences and Sanofi enter deal with USD 6bn potential

US-based IGM Biosciences has signed a deal with French Sanofi to use the company’s ”super molecule” technology to develop drug candidates within oncology, immunology and inflammation.


In the midst of a greater stock fluctuation for US-based IGM Biosciences, the company has entered a multimillion-dollar deal with French Sanofi, a competitor of Novo Nordisk on the insulin area. In aggregate numbers, the deal could reach over USD 6bn, a joint press release reports.

A more modest USD 150m starts the partnership off, with IGM Biosciences being the recipient of the upfront payment while Sanofi further expresses an interest in purchasing IGM shares for up to USD 100m.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs